GL Pharm Tech Corp. Stock

Stocks

A204840

KR7204840003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2026-07-16			5-day change	1st Jan Change
814.00 ^KRW	+0.12%		+0.12%	-25.39%

05-19	Gl Pharm Tech Corp - Announces Reverse Stock Split	RE
24-05-02	An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion.	CI

Valuation: GL Pharm Tech Corp.

Market Cap	63.12B 42.79M 37.63M 34.96M 32.15M 60.3M 4.14B 61.38M 418M 163M 2.02B 161M 157M 7.01B	P/E 2024	-31x	P/E 2025	6,738x
Enterprise Value	78.82B 53.43M 46.99M 43.66M 40.15M 75.3M 5.17B 76.65M 522M 204M 2.52B 201M 196M 8.76B	EV / Sales 2024	3.28x	EV / Sales 2025	2.84x
Free-Float	70.23%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: GL Pharm Tech Corp.

Dynamic Chart

Latest news : GL Pharm Tech Corp.

05-19	Gl Pharm Tech Corp - Announces Reverse Stock Split	RE
24-05-02	An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion.	CI
24-03-05	W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund	CI
24-03-05	GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.	CI
23-09-14	GL Pharm Tech to Raise 9.2 Billion Won via Share Issuance; Shares Decline 7%	MT
23-09-13	GL Pharm Tech Corp. announced that it expects to receive KRW 9.199999458 billion in funding from W Science Co., Ltd.	CI
23-09-13	W Science Co., Ltd. agreed to acquire a 14.7% stake in GL Pharm Tech Corp.	CI
23-05-08	GL Pharm Tech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-03-16	GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt	CI
22-03-16	GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt	CI
20-11-22	GL Pharm Tech Corp. announced that it expects to receive KRW 8.999999634 billion in funding from Ideal Private Equity Fund	CI
20-09-28	GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.	CI
20-09-20	GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.	CI

More news

Quotes and Performance

1 day	+0.12%
1 week	+0.12%
Current month	-2.05%
1 month	-7.29%
3 months	-22.62%
6 months	-21.05%
Current year	-25.39%

More quotes

Course Extremes

1 month	778	935
Current year	778	1,195
1 year	778	1,330
3 years	705	1,844
5 years	655	1,844
10 years	390	8,450

More quotes

Managers and Directors: GL Pharm Tech Corp.

Manager	Title	Age	Since
Yong-Il Kim CEO	Chief Executive Officer	47	2024-03-18
Seong-Pil Jin CEO	Chief Executive Officer	57	2024-03-18
Young-Pil Kim DFI	Director of Finance/CFO	47	-

Director	Title	Age	Since
Han-Gon Choi BRD	Director/Board Member	65	2024-02-27
Seong-Pil Jin BRD	Director/Board Member	57	2024-03-18
Yong-Il Kim BRD	Director/Board Member	47	2024-03-18

More insiders

Latest insider transactions

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/13/24	Ideal Private Equity Co., Ltd.	Sell	Company	9,242	0.0147%
3/13/24	Ideal Private Equity Co., Ltd.	Sell	Company	4,886,450	7.7704%
3/12/24	Hun-Sik Wang	Sell		915,696	1.4561%

Transaction History

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GL PHARM TECH CORP.	+0.12%	+0.12%	-30.90%	-25.05%	42.75M
LONZA GROUP AG	+1.08%	-5.74%	-4.98%	+11.68%	46.06B
REVOLUTION MEDICINES, INC.	+4.03%	+5.63%	+404.32%	+629.65%	38.91B
BEONE MEDICINES AG	+14.93%	+3.26%	+11.17%	+67.88%	35.57B
IQVIA HOLDINGS INC.	+5.94%	-1.80%	+6.42%	-9.40%	33.13B
CELLTRION, INC.	+1.23%	-1.99%	-0.05%	+30.76%	26.42B
ASCENDIS PHARMA A/S	+4.98%	-2.65%	-	-	16.61B
MEDPACE HOLDINGS, INC.	+14.15%	+13.17%	+39.17%	+146.52%	15.08B
EUROFINS SCIENTIFIC SE	-6.32%	-4.59%	+4.36%	+8.22%	14.08B
ICON PUBLIC LIMITED COMPANY	-6.72%	+0.27%	+1.53%	-29.74%	12.81B
Average	+2.42%	-2.24%	+47.89%	+92.28%	23.87B
Weighted average by Cap.	+2.65%	-2.47%	+75.56%	+134.61%

See all sector performances

Financials

	2024	2025
Net sales	26.05B 17.66M 15.53M 14.43M 13.27M 24.88M 1.71B 25.33M 173M 67.29M 834M 66.29M 64.85M 2.89B	35.27B 23.91M 21.03M 19.53M 17.96M 33.69M 2.32B 34.29M 234M 91.11M 1.13B 89.75M 87.81M 3.92B
Net income	-2.34B -1.58M -1.39M -1.29M -1.19M -2.23M -153M -2.27M -15.48M -6.04M -74.84M -5.95M -5.82M -260M	12.49M 8.47K 7.45K 6.92K 6.36K 11.93K 820K 12.14K 82.71K 32.26K 400K 31.78K 31.09K 1.39M
Net Debt	10.39B 7.04M 6.2M 5.76M 5.29M 9.93M 682M 10.11M 68.83M 26.85M 333M 26.45M 25.88M 1.15B	15.7B 10.64M 9.36M 8.69M 8M 14.99M 1.03B 15.26M 104M 40.55M 503M 39.95M 39.08M 1.74B

* Estimated data More financial data

Company Profile

GL Pharm Tech Corp., formerly IBKS No.2 Special Purpose Acquisition Company, is a Korea-based company mainly engaged in the research and development of pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-11 Significant Split/Dividend

More about the company